Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

N-Acetylcysteine treatment reduces TNF-alpha levels and myonecrosis in diaphragm muscle of mdx mice

Texto completo
Autor(es):
Moraes Pinto, Rafael de Senzi [1] ; Ferretti, Renato [1] ; Rapucci Moraes, Luis Henrique [1] ; Neto, Humberto Santo [1] ; Marques, Maria Julia [1] ; Minatel, Elaine [1]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Biol Estrutural & Func, BR-13083970 Campinas, SP - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: Clinical Nutrition; v. 32, n. 3, p. 472-475, JUN 2013.
Citações Web of Science: 20
Resumo

Background \& aims: Duchenne muscular dystrophy (DMD) is a genetic muscle disease caused by the absence of dystrophin. An established animal model of DMD is the mdx mouse, which is unable to express dystrophin. Inflammation, particularly the proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha), strongly contributes to necrosis in the dystrophin-deficient fibers of the mdx mice and in DMD. In this study we investigated whether the antioxidant N-acetylcysteine (NAC) decreases TNF-alpha levels and protects the diaphragm muscle of mdx mice against necrosis. Methods: Mdx mice (14 days old) received daily intraperitoneal injections of NAC for 14 days, followed by removal of the diaphragm muscle. Control mdx mice were injected with saline. Results: NAC reduced TNF-alpha and 4-HNE-protein adducts levels, inflammation, creatine kinase levels, and myonecrosis in diaphragm muscle. Conclusions: NAC may be used as a complementary treatment for dystrophinopathies. However, clinical trials are needed to determine the appropriate dose for patients with Duchenne muscular dystrophy. (C) 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. (AU)

Processo FAPESP: 10/01087-4 - Tratamento in vivo e in vitro com a associação de N-acetilcisteína e deferoxamina em camundongos distróficos
Beneficiário:Luis Henrique Rapucci Moraes
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 08/50731-3 - Tratamento in vivo e in vitro com N-acetilcisteína (NAC) em camundongos distróficos
Beneficiário:Elaine Minatel
Linha de fomento: Auxílio à Pesquisa - Regular